Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Patient safety

Mortality risk should be considered with choice of sulfonylurea drug

Some sulfonylurea drugs, such as gliclazide and glimepiride, are associated with a lower mortality risk than others.

Glipizide drug molecule. Glipizide, a sulfonylurea drug, is associated to lower mortality risk when treating diabetes, study finds

Source: Laguna Design / Science Photo Library

Mortality risk varies between different sulfonylurea drugs, with a lower risk associated with glipizide (pictured)

Clinicians should bear in mind the varied mortality rates between sulfonylurea (SU) drugs, which are lower with gliclazide and glimepiride than with glibenclamide, when prescribing these drugs for diabetes, write the authors of a meta-analysis published in The Lancet Diabetes & Endocrinology[1] on 23 October 2014.

SUs differ with regard to tissue selectivity and risk of hypoglycaemia, and there is ongoing debate about their cardiovascular safety. To assess potential differences, Scot Simpson, from the University of Alberta, Edmonton, Canada, and co-authors searched literature for controlled studies reporting risks of all-cause mortality, cardiovascular mortality or myocardial infarction for at least two SUs.

Their final analysis included 18 studies involving 167,327 patients of whom 14,970 (9%) died. Using standard meta-analysis of direct evidence, gliclazide had the lowest risk of mortality, followed by glimepiride, glipizide, glibenclamide, tolbutamide and chlorpropamide. But when using network meta-analysis, which incorporates both direct and indirect evidence, gliclazide and glimepiride were associated with a significantly lower risk of mortality compared with glibenclamide, whereas glipizide had a similar risk.

Compared with glibenclamide, the relative risk of death was 0.65 for gliclazide, 0.83 for glimepiride, 0.98 for glipizide, 1.13 for tolbutamide, and 1.34 for chlorpropamide. Similar associations were noted for cardiovascular-related mortality, whereas there were no differences in risk of myocardial infarction among the various SUs.

“Findings from this study should be considered hypothesis-generating and need to be verified in a properly designed randomised clinical trial,” the authors conclude, adding that results from ongoing studies (TOSCA IT and CAROLINA) will provide further insights about the use of SUs in diabetes management.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066979

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.